Satellos Bioscience (TSE:MSCL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Satellos Bioscience, a biotech firm focusing on muscle disease treatments, announced CEO Frank Gleeson will join a panel at the PPMD Annual Conference to discuss their progress, particularly their investment-backed oral drug candidate aimed at treating Duchenne muscular dystrophy. The company is preparing to submit a regulatory package for a Phase 1 clinical trial of SAT-3247, a novel drug designed to restore muscle regeneration. SAT-3247, which targets the underlying cause of muscle loss in degenerative diseases, is anticipated to enter human trials in the third quarter of 2024.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.